GleamWall
中文EN

BYSI BeyondSpring Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1677940 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7,733.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA185.0%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.2%
Debt / equity0.00x
Current ratio0.28x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.35x
Accruals ratio250.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$4.39M$2.64M
SG&A expense$4.56M$6.11M
Operating income-$8.95M-$8.75M
Pretax income-$8.62M-$8.77M
Income tax$90,000$96,000
Net income-$1.01M-$11.12M
EBITDA-$8.86M-$8.47M
EPS (basic)-0.02-0.28
EPS (diluted)——
Balance sheet
Cash & equivalents$2.97M$2.00M
Short-term investments$1.00M$0
Current assets$20.88M$28.58M
PP&E, net$155,000$239,000
Total assets$25.93M$34.31M
Current liabilities$13.58M$11.01M
Total liabilities$49.92M$48.60M
Shareholders' equity-$32.16M-$32.90M
Shares outstanding41.12M40.32M
Cash flow statement
Operating cash flow-$19.77M-$16.44M
Capital expenditure$50,000$224,000
Free cash flow-$19.82M-$16.67M
Investing cash flow$10.79M-$12.01M
Financing cash flow$4.97M$26.79M
Depreciation & amortization$87,000$285,000
Stock-based compensation$722,000$2.25M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.